Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 20 | Koetje Todd MSee Remarks. | Grant or award | A | $193K 2,198 sh | Feb 4, 2026 |
| 20 | Detz Margaret MasonerChief People Officer | Grant or award | A | $125K 1,422 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 20 | Schwartz Richard ToddDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $4.35M 247.1K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 19 | Moore Alexander D.Director | Open-market sale · 10b5-1 plan | SELL | $186K 1,233 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open-market sale · 10b5-1 plan | SELL | $378K 1,639 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 19 | Morris Philip CDirector | Grant or award | A | $27K 818 sh | Feb 4, 2026 traded Jan 28, 2026 |
| 19 | Metzfield DennisVP, PAO & Controller | Tax withholding | F | $20K 229 sh | Feb 4, 2026 traded Jan 30, 2026 |
| 19 | Bachrodt AmySVP, Finance | Open-market sale · 10b5-1 plan | SELL | $187K 4,064 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moore Alexander D.Director | Open-market sale · 10b5-1 plan | SELL | $106K 720 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Jones Jeanne MEVP, CFO, Audit & Risk | Disposition to issuer | D | $314K 7,154 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | France NatashaSEE REMARKS | Option exercise | M | — 10.4K sh | Feb 4, 2026 traded Feb 1, 2026 |
| 19 | Duffy Kristine DDirector | Grant or award | A | $27K 818 sh | Feb 4, 2026 traded Jan 28, 2026 |
| 18 | Howse CurtisSee remarks | Open-market sale · 10b5-1 plan | SELL | $3.80M 52.6K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Prieskorn Laura LoueneDirector, CEO and President | Grant or award | A | — 146.5K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Bendza Gary MarkEVP, CFO | Grant or award | A | — 483.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Cummings Don WEVP and CFO | Grant or award | A | — 14.1K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Raub ChristopherExecutive Vice President | Grant or award | A | — 11.2K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Chelko CarrieEVP and General Counsel | Grant or award | A | — 25.9K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Gutman CarrieSenior Vice President | Grant or award | A | — 763 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Jones Jeanne MEVP, CFO, Audit & Risk | Option exercise | M | — 24.7K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malenka Robert C.Director | Open-market sale | SELL | $18 1 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 17 | Malabre Richard CSVP, Chief Accounting Officer | Open-market sale · 10b5-1 plan | SELL | $50K 36.1K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Hill Donna K.VP, Human Resources | Grant or award | A | — 17.1K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Smith NathanChief Financial Officer | Tax withholding | F | $79K 3,859 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Stetz MattiasChief Operating Officer | Open-market sale · 10b5-1 plan | SELL | $353K 20.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open-market sale · 10b5-1 plan | SELL | $133K 576 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Robinson-Gay DonaldSenior Vice President | Tax withholding | F | $57K 939 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Clark Kyra ESenior Vice President | Tax withholding | F | $63K 1,045 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Frost DianaDirector | Tax withholding | F | $57K 548 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open-market sale · 10b5-1 plan | SELL | $202K 878 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open-market sale · 10b5-1 plan | SELL | $140K 600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open-market sale · 10b5-1 plan | SELL | $197K 850 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Kleczynski Robert ASVP, Controller & Tax | Tax withholding | F | $165K 3,768 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Kleczynski Robert ASVP, Controller & Tax | Disposition to issuer | D | $218K 4,963 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 15 | Munari Alvise J.Chief Product Officer | Tax withholding | F | $274K 438 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 15 | White Daniel JamesDirector | Grant or award | A | $27K 818 sh | Feb 4, 2026 traded Jan 28, 2026 |
| 15 | Dawsey James MDirector | Grant or award | A | $27K 818 sh | Feb 4, 2026 traded Jan 28, 2026 |
| 15 | Frew JamesSEE REMARKS | Option exercise | M | — 50.6K sh | Feb 4, 2026 traded Feb 1, 2026 |
| 15 | Jahnel DarrinDirector | Grant or award | A | $2,238 69 sh | Feb 4, 2026 traded Jan 28, 2026 |
| 15 | Furbee DanielDirector, SEE REMARKS | Option exercise | M | — 51.6K sh | Feb 4, 2026 traded Feb 1, 2026 |